Overview

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

Status:
Terminated

Trial end date:
2018-05-15

Target enrollment:

Participant gender:

Summary

This is a Phase 2 study to evaluate the combination of denintuzumab mafodotin in combination with RCHOP or RCHP compared with RCHOP alone as front-line therapy in patients with diffuse large B-cell lymphoma or follicular lymphoma Grade 3b.

Phase:

Phase 2

Details

Lead Sponsor:

Seagen Inc.
Seattle Genetics, Inc.

Treatments:

Antibodies
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Cyclophosphamide
Doxorubicin
Liposomal doxorubicin
Prednisone
Rituximab
Vincristine